Actively Recruiting
Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma
Led by Tao Liu · Updated on 2025-11-21
143
Participants Needed
2
Research Sites
163 weeks
Total Duration
On this page
Sponsors
T
Tao Liu
Lead Sponsor
T
Tianjin Medical University General Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This clinical study aims to learn about the efficacy and safety of aspirin continuation or discontinuation in conservative treatment for chronic subdural hematoma. All participants received standard conservative treatment for chronic subdural hematoma, with a randomized intervention to either continue or discontinue aspirin administration. By participating in this study, participants can receive additional scientific guidance on aspirin medication management beyond routine conservative treatment, thereby optimizing individualized therapy.
CONDITIONS
Official Title
Aspirin Continuation or Discontinuation in Conservative Treatment for Chronic Subdural Hematoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, male or female
- Confirmed diagnosis of chronic subdural hematoma by cranial CT and/or MRI
- Planned conservative management without surgical evacuation
- Regular aspirin use at the time of enrollment
- Signed informed consent by patient or legal representative
You will not qualify if you...
- Need for emergency surgery to remove hematoma at enrollment
- Use of other anticoagulants or antiplatelet drugs that cannot be stopped per study protocol
- Chronic subdural hematoma caused by other conditions like shunt drainage or brain tumors
- Active bleeding or major heart events (e.g., recent heart attack, unstable angina, revascularization) within 30 days before enrollment
- Known bleeding disorders such as hemophilia or severe thrombocytopenia
- Inability to provide informed consent or expected difficulty completing follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Xuanwu Hospital Capital Medical University
Beijing, China
Actively Recruiting
2
Tianjin Medical University General Hospital
Tianjin, China
Actively Recruiting
Research Team
T
Tao Liu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here